MCID: SKN022
MIFTS: 40

Skin Squamous Cell Carcinoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Skin Squamous Cell Carcinoma

MalaCards integrated aliases for Skin Squamous Cell Carcinoma:

Name: Skin Squamous Cell Carcinoma 12 14
Squamous Cell Carcinoma of Skin 12 69
Epidermoid Skin Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3151
NCIt 47 C4819
SNOMED-CT 64 254651007
UMLS 69 C0553723

Summaries for Skin Squamous Cell Carcinoma

Disease Ontology : 12 A skin carcinoma that has material basis in squamous cells.

MalaCards based summary : Skin Squamous Cell Carcinoma, also known as squamous cell carcinoma of skin, is related to palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal and pseudovascular skin squamous cell carcinoma. An important gene associated with Skin Squamous Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Immune response IL-23 signaling pathway. The drugs Cetuximab and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Related Diseases for Skin Squamous Cell Carcinoma

Graphical network of the top 20 diseases related to Skin Squamous Cell Carcinoma:



Diseases related to Skin Squamous Cell Carcinoma

Symptoms & Phenotypes for Skin Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.78 IL10 SEM1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.78 CD151
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.78 SEM1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.78 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.78 IL10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.78 IL10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-131 9.78 SEM1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.78 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.78 SEM1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.78 IL10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.78 SEM1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.78 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.78 IL10 CD151
14 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.78 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.78 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.78 CD151
17 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.78 IL10
18 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.78 CD151
19 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.78 CD151
20 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.78 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.78 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.78 SEM1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.78 SEM1 CD151 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.78 IL10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.78 IL10

MGI Mouse Phenotypes related to Skin Squamous Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.61 IL10 KLF4 STAT1 STAT2 TNFAIP8L2 TP53
2 neoplasm MP:0002006 9.17 CD151 EIF4E IL10 KLF4 MGMT STAT1

Drugs & Therapeutics for Skin Squamous Cell Carcinoma

Drugs for Skin Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4,Phase 3,Phase 2 205923-56-4 56842117 2333
2
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
3
Fluorouracil Approved Phase 4,Phase 2 51-21-8 3385
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
5
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
6
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
9
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
10
Ethanol Approved Phase 4 64-17-5 702
11
Acitretin Approved Phase 4,Phase 2 55079-83-9 6437841 5284513
12
Petrolatum Approved Phase 4 8009-03-8
13 Titanium dioxide Approved Phase 4 13463-67-7
14
Azathioprine Approved Phase 4 446-86-6 2265
15
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
16
Mycophenolic acid Approved Phase 4 24280-93-1 446541
17
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
18 Adjuvants, Immunologic Phase 4
19 Interferon Inducers Phase 4,Phase 2
20 interferons Phase 4,Phase 1,Phase 2
21 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Antimetabolites Phase 4,Phase 2
23 Antimetabolites, Antineoplastic Phase 4,Phase 2
24 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Tin Fluorides Phase 4
27 triamcinolone acetonide Phase 4,Phase 2
28 Triamcinolone diacetate Phase 4,Phase 2
29 Triamcinolone hexacetonide Phase 4,Phase 2
30 Analgesics Phase 4,Phase 2
31 Analgesics, Non-Narcotic Phase 4,Phase 2
32 Anti-Inflammatory Agents Phase 4,Phase 2
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
34 Antirheumatic Agents Phase 4,Phase 3,Phase 2
35 Cyclooxygenase Inhibitors Phase 4,Phase 2
36 Peripheral Nervous System Agents Phase 4,Phase 2
37 Retinol palmitate Phase 4
38 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
39 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
40 Antifungal Agents Phase 4,Phase 3,Phase 2
41 Calcineurin Inhibitors Phase 4,Phase 3
42 Cyclosporins Phase 4,Phase 3
43 Keratolytic Agents Phase 4,Phase 3,Phase 2
44 Anti-Allergic Agents Phase 4
45 mometasone furoate Phase 4 83919-23-7
46 retinol Nutraceutical Phase 4
47
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
48
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
49
Aminolevulinic acid Approved Phase 3,Phase 2,Early Phase 1 106-60-5 137
50
Dapsone Approved, Investigational Phase 3 80-08-0 2955

Interventional clinical trials:

(show top 50) (show all 177)

id Name Status NCT ID Phase Drugs
1 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
2 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
3 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
4 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
5 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
6 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Recruiting NCT02495064 Phase 4 Mometasone Furoate Cream
7 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
8 Acitretin Plasma Levels Under Hemodialysis Suspended NCT00488384 Phase 4 Chemopreventive application (Acitretin)
9 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
10 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
11 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
12 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
13 Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Completed NCT00005884 Phase 3 eflornithine
14 TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients Completed NCT00133887 Phase 3 rapamycin;ciclosporine;tacrolimus
15 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
16 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
17 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
18 Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
19 Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
20 A Comparative Study of the Healing of Chronic Ulcers of Recessive Epidermolysis Bullosa : Dressing vs Amniotic Membrane Recruiting NCT02286427 Phase 3
21 E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck Recruiting NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
22 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Active, not recruiting NCT01362140 Phase 3 Darbepoetin alfa;Placebo
23 A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp Enrolling by invitation NCT03115476 Phase 3 ingenol disoxate gel 0.018%;ingenol disoxate gel 0.037%
24 Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients Terminated NCT01532453 Phase 3
25 Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC) Unknown status NCT01129154 Phase 2 infusions of Panitumumab
26 Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
27 Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer Unknown status NCT00003097 Phase 2
28 Treatment Selection According to Skin Reaction to Cetuximab Unknown status NCT01472653 Phase 2 cisplatin;cetuximab
29 Phase II AK Study in Organ Transplant Patients Unknown status NCT00829192 Phase 2 Afamelanotide (CUV1647);Placebo
30 A Study of Intensity-modulated Radiotherapy in Patients With Squamous Cell Carcinoma of Unknown Primary (SCCUP) of the Head and Neck Unknown status NCT02112344 Phase 1, Phase 2
31 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Completed NCT00126555 Phase 2 Gefitinib
32 Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR Completed NCT00240682 Phase 2 cetuximab
33 Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Completed NCT00563290 Phase 2 dasatinib
34 Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ Completed NCT00329121 Phase 2 PEP005
35 An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS) Completed NCT00652080 Phase 1, Phase 2 API 31510
36 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT00054691 Phase 2 Iressa
37 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma Completed NCT00369512 Phase 2 Erlotinib
38 Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis Completed NCT02085395 Phase 2 SR-T100 ® Gel
39 Photodynamic Therapy in Treating Patients With Skin Cancer Completed NCT00002963 Phase 2 aminolevulinic acid hydrochloride
40 Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck Completed NCT00519077 Phase 2 Gefitinib
41 Photodynamic Therapy in Treating Patients With Skin Cancer Completed NCT00002975 Phase 2 aminolevulinic acid
42 Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis Completed NCT00021294 Phase 2 eflornithine;triamcinolone
43 T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant Completed NCT00089180 Phase 2 liposomal T4N5 lotion
44 Investigation of a Behavioral Substitute for Sunbathing Completed NCT00403377 Phase 1, Phase 2
45 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
46 SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck Completed NCT00006361 Phase 2 semaxanib
47 Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer Completed NCT00002506 Phase 2 isotretinoin
48 Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck Completed NCT00063895 Phase 1, Phase 2 erlotinib hydrochloride
49 Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer Completed NCT00791141 Phase 2 Cetuximab
50 Photochemical Tissue Bonding Completed NCT00586040 Phase 2

Search NIH Clinical Center for Skin Squamous Cell Carcinoma

Genetic Tests for Skin Squamous Cell Carcinoma

Anatomical Context for Skin Squamous Cell Carcinoma

MalaCards organs/tissues related to Skin Squamous Cell Carcinoma:

39
Skin, Kidney, Lung, Testes, Lymph Node, Bone, Monocytes

Publications for Skin Squamous Cell Carcinoma

Articles related to Skin Squamous Cell Carcinoma:

(show top 50) (show all 67)
id Title Authors Year
1
Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1. ( 28672959 )
2017
2
A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma. ( 28507641 )
2017
3
Lgr6 is a stem cell marker in mouse skin squamous cell carcinoma. ( 28945253 )
2017
4
Cancer cell of origin controls epithelial-to-mesenchymal transition in skin squamous cell carcinoma. ( 28607908 )
2017
5
Correlation Between Microvessel Density and Morphological Features in Skin Squamous Cell Carcinoma. ( 28593886 )
2017
6
Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth inA vitro and inA vivo. ( 28623128 )
2017
7
CCR5-dependent homing of T regulatory cells to the tumor microenvironment contributes to skin squamous cell carcinoma development. ( 28904130 )
2017
8
Quantitative phosphoproteomic analysis reveals system-wide signaling pathways regulated by site-specific phosphorylation of Keratin-8 in skin squamous cell carcinoma derived cell line. ( 28176443 )
2017
9
Erratum: Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. ( 26845409 )
2016
10
DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma. ( 27471605 )
2016
11
Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology. ( 27714753 )
2016
12
Antimicrobial peptide LL-37 promotes the proliferation and invasion of skin squamous cell carcinoma by upregulating DNA-binding protein A. ( 27588122 )
2016
13
The genetic evolution of skin squamous cell carcinoma: tumor suppressor identity matters. ( 27193637 )
2016
14
Inhibitory effect of curcumin on invasion of skin squamous cell carcinoma a431 cells. ( 25854367 )
2015
15
TIPE2 regulates tumor-associated macrophages in skin squamous cell carcinoma. ( 26577853 )
2015
16
Clinical significance of STAT3 and MAPK phosphorylation, and the protein expression of cyclin D1 in skin squamous cell carcinoma tissues. ( 26497194 )
2015
17
Inhibition of skin squamous cell carcinoma proliferation and promote apoptosis by dual silencing of NET-1 and survivin. ( 26080853 )
2015
18
Autophagy in human skin squamous cell carcinoma: Inhibition by 3-MA enhances the effect of 5-FU-induced chemotherapy sensitivity. ( 26398820 )
2015
19
Inhibitory effect of berberine on human skin squamous cell carcinoma A431 cells. ( 26400287 )
2015
20
Exposure to moxifloxacin and cytomegalovirus replication is associated with skin squamous cell carcinoma development in lung transplant recipients. ( 26403508 )
2015
21
Ginsenoside rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma. ( 25966742 )
2015
22
Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. ( 26168291 )
2015
23
Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp. ( 26391010 )
2015
24
Skin squamous cell carcinoma presenting as cellulitis. ( 25635168 )
2015
25
Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. ( 25915530 )
2015
26
Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia. ( 25358582 )
2014
27
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism. ( 24917395 )
2014
28
Advanced skin squamous cell carcinoma: role of radiotherapy. ( 24563891 )
2014
29
Sox2, a marker for stem-like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma. ( 25061226 )
2014
30
Clinical significance of methylation of E-cadherin and p14ARF gene promoters in skin squamous cell carcinoma tissues. ( 25126184 )
2014
31
Lgr5-positive cells are cancer stem cells in skin squamous cell carcinoma. ( 25135431 )
2014
32
Tetraspanin CD151 plays a key role in skin squamous cell carcinoma. ( 22824799 )
2013
33
Immunohistochemical analysis of O(6)-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma. ( 23460078 )
2013
34
The inhibition of resveratrol to human skin squamous cell carcinoma A431 xenografts in nude mice. ( 23428654 )
2013
35
Expression and function of NET-1 in human skin squamous cell carcinoma. ( 24196235 )
2013
36
HPV type 16-induced skin squamous cell carcinoma located on the groin of immunocompetent patients. ( 24116660 )
2013
37
Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness. ( 23188079 )
2012
38
Pronounced allelic imbalance at D9S162 in skin squamous cell carcinoma of organ transplant recipients. ( 22508773 )
2012
39
Upregulation of TCTP expression in human skin squamous cell carcinoma increases tumor cell viability through anti-apoptotic action of the protein. ( 22969908 )
2012
40
C/EBPI+ expression is downregulated in human nonmelanoma skin cancers and inactivation of C/EBPI+ confers susceptibility to UVB-induced skin squamous cell carcinomas. ( 21346772 )
2011
41
The incidence of skin squamous cell carcinoma in Osijek-Baranja County--an epidemiological study. ( 22220409 )
2011
42
Involvement of VILIP-1 (visinin-like protein) and opposite roles of cyclic AMP and GMP signaling in in vitro cell migration of murine skin squamous cell carcinoma. ( 21480386 )
2011
43
Curcumin inhibits skin squamous cell carcinoma tumor growth in vivo. ( 21493306 )
2011
44
[Expression, clinical and pathological significance of KIAA1173 gene in skin squamous cell carcinoma]. ( 20646595 )
2010
45
Immune phenotype of peripheral blood cells and skin squamous cell carcinoma in organ transplant recipients. ( 20441422 )
2010
46
Association of the DSS1 c.143G>A polymorphism with skin squamous cell carcinoma. ( 20220765 )
2010
47
[Functions of NET-1 gene in skin squamous cell carcinoma cell line (A431): a siRNA study]. ( 20078975 )
2009
48
Desipramine inhibits the growth of a mouse skin squamous cell carcinoma cell line and affects glucocorticoid receptor-mediated transcription. ( 19575421 )
2009
49
The preventive effect of calcitriol on skin squamous cell carcinoma may be due to its effect on prostaglandin E2 metabolism and biologic activity. ( 20021988 )
2009
50
Etretinate enhances the susceptibility of human skin squamous cell carcinoma cells to 5-aminolaevulic acid-based photodynamic therapy. ( 19077103 )
2009

Variations for Skin Squamous Cell Carcinoma

ClinVar genetic disease variations for Skin Squamous Cell Carcinoma:

6 (show all 22)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
3 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
4 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
5 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
6 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
7 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
8 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
9 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
10 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
11 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
12 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
13 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
14 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
15 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
16 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
17 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
18 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
19 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
20 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
21 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic/Likely pathogenic rs876659802 GRCh37 Chromosome 17, 7577105: 7577105
22 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211

Cosmic variations for Skin Squamous Cell Carcinoma:

9 (show top 50) (show all 3347)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM703213 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1817C>T p.P606L 13
2 COSM4990873 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.878C>T p.S293L 13
3 COSM4990875 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.247C>T p.P83S 13
4 COSM4990309 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13
5 COSM4990310 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13
6 COSM4991869 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.282C>G p.A94A 13
7 COSM4991865 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.522C>T p.F174F 13
8 COSM4991861 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.876G>C p.P292P 13
9 COSM4991863 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.569A>C p.K190T 13
10 COSM4991867 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.314T>G p.V105G 13
11 COSM4990301 ZIC2 skin,NS,carcinoma,squamous cell carcinoma c.915G>A p.E305E 13
12 COSM3184673 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.569C>T p.P190L 13
13 COSM3184669 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.596C>T p.T199I 13
14 COSM4991542 ZBED4 skin,NS,carcinoma,squamous cell carcinoma c.328C>T p.R110W 13
15 COSM4993525 ZBED1 skin,NS,carcinoma,squamous cell carcinoma c.601T>G p.W201G 13
16 COSM4991780 XPO1 skin,NS,carcinoma,squamous cell carcinoma c.2285G>A p.W762* 13
17 COSM4991846 XPC skin,NS,carcinoma,squamous cell carcinoma c.2446G>A p.E816K 13
18 COSM4991849 XPC skin,NS,carcinoma,squamous cell carcinoma c.2254C>T p.P752S 13
19 COSM4829120 XPC skin,NS,carcinoma,squamous cell carcinoma c.1439C>T p.S480F 13
20 COSM4991848 XPC skin,NS,carcinoma,squamous cell carcinoma c.2255C>T p.P752L 13
21 COSM4991847 XPC skin,NS,carcinoma,squamous cell carcinoma c.2445G>A p.E815E 13
22 COSM4990181 WT1 skin,NS,carcinoma,squamous cell carcinoma c.726C>A p.N242K 13
23 COSM4990704 VTI1B skin,NS,carcinoma,squamous cell carcinoma c.274C>T p.H92Y 13
24 COSM4991823 UMPS skin,NS,carcinoma,squamous cell carcinoma c.331G>A p.G111R 13
25 COSM4991826 UMPS skin,NS,carcinoma,squamous cell carcinoma c.843G>A p.K281K 13
26 COSM4991824 UMPS skin,NS,carcinoma,squamous cell carcinoma c.332G>A p.G111E 13
27 COSM4990646 TTLL7 skin,NS,carcinoma,squamous cell carcinoma c.1501-1G>A p.? 13
28 COSM4990645 TTLL7 skin,NS,carcinoma,squamous cell carcinoma c.1501G>A p.E501K 13
29 COSM4990647 TTLL7 skin,NS,carcinoma,squamous cell carcinoma c.1001G>A p.G334E 13
30 COSM4990723 TSHR skin,NS,carcinoma,squamous cell carcinoma c.1459G>A p.D487N 13
31 COSM4990715 TSHR skin,NS,carcinoma,squamous cell carcinoma c.91T>C p.C31R 13
32 COSM3498383 TSHR skin,NS,carcinoma,squamous cell carcinoma c.1248C>T p.F416F 13
33 COSM4990717 TSHR skin,NS,carcinoma,squamous cell carcinoma c.171-1G>A p.? 13
34 COSM4990721 TSHR skin,NS,carcinoma,squamous cell carcinoma c.693-1G>A p.? 13
35 COSM4990719 TSHR skin,NS,carcinoma,squamous cell carcinoma c.492G>A p.M164I 13
36 COSM4990722 TSHR skin,NS,carcinoma,squamous cell carcinoma c.937A>T p.K313* 13
37 COSM4990848 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.1846G>A p.D616N 13
38 COSM4990850 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.2587G>A p.E863K 13
39 COSM4423739 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.2615C>T p.S872F 13
40 COSM4990854 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.2707C>T p.P903S 13
41 COSM4990856 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.3330C>T p.A1110A 13
42 COSM4990845 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.1153C>T p.H385Y 13
43 COSM4606358 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.1378G>A p.A460T 13
44 COSM4993227 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2880G>A p.L960L 13
45 COSM4993232 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.1993A>G p.N665D 13
46 COSM4993230 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2640G>A p.M880I 13
47 COSM4993229 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2750C>T p.A917V 13
48 COSM4993231 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2208+1G>A p.? 13
49 COSM4993226 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2881G>A p.E961K 13
50 COSM4993228 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2751C>T p.A917A 13

Expression for Skin Squamous Cell Carcinoma

Search GEO for disease gene expression data for Skin Squamous Cell Carcinoma.

Pathways for Skin Squamous Cell Carcinoma

Pathways related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.61 BIRC5 EIF4E IL10 SEM1 STAT1 STAT2
2
Show member pathways
12.2 BIRC5 IL10 STAT1 TP53
3
Show member pathways
11.94 IL10 STAT1 STAT2
4 11.9 BIRC5 STAT1 TP53
5
Show member pathways
11.79 IL10 STAT1 STAT2
6
Show member pathways
11.76 EIF4E STAT1 TP53
7 11.73 STAT1 STAT2 TP53
8 11.58 IL10 STAT1 STAT2
9
Show member pathways
11.53 IL10 STAT1 STAT2
10 11.34 BIRC5 EIF4E TP53
11 11.07 EIF4E STAT1 STAT2
12 10.98 BIRC5 IL10 STAT1 TP53
13
Show member pathways
10.84 STAT1 STAT2

GO Terms for Skin Squamous Cell Carcinoma

Biological processes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.46 EIF4E STAT1 STAT2 TP53
2 regulation of type I interferon-mediated signaling pathway GO:0060338 9.26 STAT1 STAT2
3 negative regulation of inflammatory response GO:0050728 9.13 IL10 KLF4 TNFAIP8L2
4 negative regulation of heterotypic cell-cell adhesion GO:0034115 8.62 IL10 KLF4

Molecular functions related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 8.92 BIRC5 EIF4E STAT1 TP53
2 histone acetyltransferase binding GO:0035035 8.65 TP53

Sources for Skin Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....